Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Gastrointestinal 1CNS 1

Conditions

Neoplasms 1Leukemia, Myeloid, Acute 1Glioma 1Cholangiocarcinoma 1

Interventions

venetoclax 124Azacitidine 96Cytarabine 71fludarabine 44Specimen Handling 38Cyclophosphamide 38Daunorubicin 27Decitabine 26Biopsy 25Idarubicin 24Granulocyte Colony-Stimulating Factor 21gilteritinib 18Injections 18fludarabine phosphate 17Whole-Body Irradiation 17Melphalan 16Busulfan 16Stem Cell Transplantation 15Mycophenolic Acid 15ivosidenib 13Cladribine 13decitabine and cedazuridine drug combination 12Gemtuzumab 12Tacrolimus 11CPX-351 11X-Rays 10Filgrastim 10revumenib 9enasidenib 9Cyclosporine 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Leukemia, Myeloid, Acute × Cytochrome P-450 CYP2C9 × Clear all
NCT07486713 2026-06-05

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡